Annals of Internal Medicine: Monitoring warfarin therapy in patients with lupus anticoagulants

Annals of Internal Medicine

Volumn 127, Issue 3, 1997, Pages 177-185

  Moll, Stephan ^b   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LUPUS ANTICOAGULANT; WARFARIN; ANTICOAGULANT AGENT; THROMBOPLASTIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG MONITORING; HUMAN; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOEMBOLISM; ADOLESCENT; ADULT; AGED; BLOOD; BLOOD CLOTTING TEST; FEMALE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MONITORING; PROSPECTIVE STUDY; REFERENCE VALUE; STANDARD;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION TESTS; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROSPECTIVE STUDIES; PROTHROMBIN TIME; REFERENCE VALUES; THROMBOEMBOLISM; THROMBOPLASTIN; WARFARIN;

EID: 0031203621     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-3-199708010-00001     Document Type: Article

References (38)

1. Coon WW, Willis PW 3d, Keller JB. Venous thromboembolism and other venous disease in the Tecumsah community health study. Circulation. 1973; 48:839-46.
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933-8.
3. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-60.
4. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685-91.
5. Simioni P, Prandoni P, Zanon E, Saracino MA, Scudeller A, Villalta S, et al. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost. 1996;76:187-9.
6. Hirsh J, Dalen JE, Deykin O, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1995;108(4 Suppl):231S-246S.
7. Kovacs MJ, Wong A, MacKinnon K, Weir K, Keeney M, Boyle E, et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost. 1994;71:727-30.
8. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303-8.
9. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993-7.
10. Rapaport SI, Le DT. Thrombosis in the antiphospholipid antibody syndrome [Letter]. N Engl J Med. 1995;333:993.
11. Mannucci PM, Canciani MT, Mari D, Meucci P. The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant. Scand J Haematol. 1979;22:423-32.
12. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988;72:512-9.
13. Horellou MH, Aurousseau MH, Boffa MC, Conrad J, Wiesel ML, Samama M. Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients. J Med. 1987;18:199-217.
14. Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med. 1996;47:533-53
15. Galli M, Beguin S, Lindhout T, Hemker CH. Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulants. Br J Haematol. 1989;72:549-55.
16. Brandt JT. Assays for phospholipid-dependent formation of thrombin and Xa: a potential method for quantifying lupus anticoagulant activity. Thromb Haemost. 1991;66:453-8.
17. Khamashta MA, Taub NA, Hunt BJ. Thrombosis in the antiphospholipid antibody syndrome [Letter]. N Engl J Med. 1995;333:666-7.
18. Rapaport SI, Ames SB, Duvall BJ. A plasma coagulation defect in SLE arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood. 1960;15:212-21.
19. Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood. 1983;61:684-92.
20. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74:1185-90.
21. Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol. 1985;62:738-45.
22. Coagulation Resource Committee. Comprehensive Coagulation Summary, Set CG2-A. Waukegan, IL: College of American Pathologists; 1996:1-32.
23. van den Besselaar AM, Lewis SM, Mannucci PM, Poller L. Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost. 1993;69:85.
24. Le DT, Weibert RT, Sevilla BK, Donnelly KJ, Rapaport SI. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med. 1994;120:552-8.
25. Skogen WF, Bushong DS, Johnson AE, Cox AC. The role of the Gla domain in the activation of bovine coagulation factor X by the snake venom XCP. Biochem Biophys Res Commun. 1983;111:14-20.
26. Egberg N, Heedman PA. Simplified performance of amidolytic factor X assay. Thromb Res. 1982;25:437-40.
27. Ciavarella N, Coccheri S, Gensini GF, Hassan HJ, Mannucci PM, Manotti C, et al. Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants. Thromb Res. 1980;19:493-502.
28. Lind SE, Callas PW, Golden EA, Joyner KA Jr, Ortel TL. Plasma levels of factors H, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinoloysis. 1997;8:48-53.
29. Khamashta MA. Management of thrombosis in the antiphospholipid syndrome. Lupus. 1996;5:463-6.
30. Slivka A, Walz E. Thrombosis in the antiphospholipid-antibody syndrome [Letter]. N Engl J Med. 1995;333:665-6.
31. Nasr SZ, Parke AL. Thrombosis in the antiphospholipid-antibody syndrome [Letter]. N Engl J Med. 1995;333:666.
32. Bick RL, Baker WF Jr. The antiphospholipid and thrombosis syndromes. Med Clin North Am. 1994;78:667-84.
33. Out HJ, de Groot PG, Hasselaar P, dan Vliet M, Derksen RH. Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis. 1989;48:1023-8.
34. Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, et al. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood. 1993;81:2958-63.
35. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108(4 Suppl):258S-275S.
36. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood. 1994;84:2854-67.
37. Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol. 1983; 79:678-82.
38. Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest. 1951;3:201-8.